Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan Dose-Ranging in Pediatric Hypertension
NCT00244634Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2003
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of candesartan cilexetil in hypertension (HTN) (4 arms), sponsored by AstraZeneca. Primary endpoint: Slope of change in trough sitting systolic blood pressure at 4 weeks. Started Sep 2003; status: completed.
02
Drugs
candesartan cilexetil
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00244634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00244634.